Liver transplantation for unresectable colorectal liver metastases: A systematic review

Journal of Surgical Oncology

Volumn 116, Issue 3, 2017, Pages 288-297

  Moris, Dimitrios ^a   Tsilimigras, Diamantis I ^b   Chakedis, Jeffery ^a   Beal, Eliza W ^a   Felekouras, Evangelos ^b   Vernadakis, Spiridon ^b   Schizas, Dimitrios ^b   Fung, John J ^c   Pawlik, Timothy M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

colorectal liver metastases; liver transplantation; unresectable

Indexed keywords

BASILIXIMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CORTICOSTEROID; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; OXALIPLATIN; RAPAMYCIN;

CANCER PROGNOSIS; CLINICAL EVALUATION; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); COLORECTAL LIVER METASTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LONG TERM CARE; META ANALYSIS (TOPIC); PATIENT SAFETY; PATIENT SELECTION; PHASE 4 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; COLORECTAL TUMOR; LIVER NEOPLASMS; LIVER RESECTION; PATHOLOGY; SECONDARY; TRANSPLANTATION;

COLORECTAL NEOPLASMS; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT;

EID: 85019579486     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24671     Document Type: Review

References (65)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–2917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012; 2012: 10–29.
3. Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006; 13:1271–1280.
4. de Haas RJ, Wicherts DA, Andreani P, et al. Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg. 2011; 253:1069–1079.
5. Saiura A, Yamamoto J, Koga R, et al. Favorable outcome after repeat resection for colorectal liver metastases. Ann Surg Oncol. 2014; 21:4293–4299.
6. House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010; 210: 752–745.
7. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012; 4:283–301.
8. Moris D, Dimitroulis D, Vernadakis S, et al. Parenchymal-sparing hepatectomy as the new doctrine in the treatment of liver-metastatic colorectal disease: beyond oncological outcomes. Anticancer Res. 2017; 37:9–14.
9. Galjart B, van der Stok EP, Rothbarth J, et al. Posttreatment surveillance in patients with prolonged disease-Free survival after resection of colorectal liver metastasis. Ann Surg Oncol. 2016; 23:3999–4007.
10. Page AJ, Cosgrove DC, Herman JM, Pawlik TM. Advances in understanding of colorectal liver metastasis and implications for the clinic. Expet Rev Gastroenterol Hepatol. 2015; 9:245–259.
11. Evrard S, Rivoire M, Arnaud J, et al. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br J Surg. 2012; 99:558–565.
12. Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011; 103:21–30.
13. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med. 2009; 360:1408–1417.
14. D'Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015; 261:353–360.
15. Starzl TE. The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955–1967). J Am Coll Surg. 2002; 195:587–610.
16. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Eng J Med. 1996; 334:693–699.
17. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157–176.
18. Le Treut YP, Gregoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013; 257:807–815.
19. Ravaioli M, Ercolani G, Neri F, et al. Liver transplantation for hepatic tumors: a systematic review. World J Gastroenterol. 2014; 20:5345–5352.
20. Kelly ME, Spolverato G, Le GN, et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. J Surg Oncol. 2015; 111:341–351.
21. Zavos G, Moris D, Kostakis ID, et al. De novo visceral malignancies in renal transplant recipients: a single center experience of 2054 recipients for more than 30 years. Exp Clin Transplant. 2015; 13:313–318.
22. Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 2009; 58:452–463.
23. Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: indications, limitations, and analysis of the current literature. Liver Transpl. 2010; 16:930–942.
24. Shukla A, Vadeyar H, Rela M, Shah S. Liver transplantation: east versus west. J Clin Exp Hepatol. 2013; 3:243–253.
25. Trotter JF. Liver transplantation around the world. Current opinion in organ transplantation 2017.
26. Moris D, Zavos G, Menoudakou G, et al. Organ donation during the financial crisis in Greece. Lancet 2016; 387:1511–1512.
27. de Boer JD, Koopman JJ, Metselaar HJ, et al. Liver transplantation with geriatric liver allografts: the current situation in Eurotransplant. Transpl Int. 2017; 30:432–433.
28. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62:1006–1012.
29. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13.
30. Uskudar O, Raja K, Schiano TD, et al. Liver transplantation is possible in some patients with liver metastasis of colon cancer. Transplant Proc. 2011; 43:2070–2074.
31. Kocman B, Mikulic D, Jadrijevic S, et al. Long-term survival after living-donor liver transplantation for unresectable colorectal metastases to the liver: case report. Transplant Proc. 2011; 43:4013–4015.
32. Hrehoret D, Alexandrescu S, Brasoveanu V, et al. Liver transplantation in a patient with unresectable colorectal liver metastases—a case report. Chirurgia (Bucur). 2013; 108:719–724.
33. Honore C, Detry O, De Roover A, et al. Liver transplantation for metastatic colon adenocarcinoma: report of a case with 10 years of follow-up without recurrence. Transplant international: official journal of the European Society for Organ. Transplantation. 2003; 16:692–693.
34. Song XM, Zhan WH, Wang JP, et al. Radical resection of gastric or colorectal carcinoma combined with liver transplantation for gastric or colorectal carcinoma with multiple hepatic metastases. Zhonghua Wei Chang Wai Ke Za Zhi. 2005; 8:419–421.
35. Aune S, Schistad G, Skulberg A. Human liver transplantation without azathioprine. Surg Gynecol Obstet. 1972; 135:727–728.
36. Line PD, Hagness M, Berstad AE, et al. A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept. Ann Surg. 2015; 262: 5–9.
37. Wang LJ, Zhang YM, Deng YL, et al. [Clinical analysis of liver transplantation in treatment of liver metastatic cancer]. Zhonghua zhong liu za zhi. 2016; 38:381–384.
38. Hagness M, Foss A, Line PD, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013; 257:800–806.
39. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991; 110:726–734. discussion 734–725.
40. Muhlbacher F, Huk I, Steininger R, et al. Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplant Proc. 1991; 23:1567–1568.
41. Dueland S, Hagness M, Line PD, et al. Is liver transplantation an option in colorectal cancer patients with nonresectable liver metastases and progression on all lines of standard chemotherapy? Ann Surg Oncol. 2015; 22:2195–2200.
42. Andersen MH, Dueland S, Hagness M, et al. Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma. Scand J Caring Sci. 2012; 26:713–719.
43. Sapisochin G. University Health Network, Toronto. Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 Feb 18] Available from: http://clinicaltrialsgov/show/NCT02864485NLMIdentifier:NCT02864485
44. Dueland S. Oslo University Hospital. Liver Transplantation and Colorectal Cancer. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 Feb 18] Available from: https://clinicaltrialsgov/show/NCT01479608NLMIdentifier:NCT01479608
45. Dueland S.University Hospital. RAPID Oslo 2014: Partial Liver Segment 2/3 Transplantation Study. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 Feb 18] Available from: https://clinicaltrialsgov/show/NCT02215889NLMIdentifier:NCT02215889
46. Adam R. Assistance Publique−Hôpitaux de Paris. Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy (TRANSMET). In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 Feb 18] Available from: https://clinicaltrialsgov/show/NCT02597348NLMIdentifier: NCT02597348
47. Spolverato G, Ejaz A, Azad N, Pawlik TM. Surgery for colorectal liver metastases: the evolution of determining prognosis. World J Gastrointest Oncol. 2013; 5:207–221.
48. Johnston FM, Mavros MN, Herman JM, Pawlik TM. Local therapies for hepatic metastases. J Natl Compr Canc Netw. 2013; 11:153–160.
49. Lv W, Zhang GQ, Jiao A, et al. Chemotherapy plus cetuximab versus chemotherapy alone for patients with KRAS wild type unresectable liver-Confined metastases colorectal cancer: an updated meta-Analysis of RCTs. Gastroenterol Res Pract. 2017; 2017:8464905.
50. Passot G, Soubrane O, Giuliante F, et al. Recent advances in chemotherapy and surgery for colorectal liver metastases. Liver Cancer. 2016; 6:72–79.
51. Zorzi D, Mullen JT, Abdalla EK, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg. 2006; 10:86–94.
52. Lalmahomed ZS, Ayez N, van der Pool AE, et al. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World J Surg. 2011; 35:656–661.
53. Wicherts DA, Miller R, de Haas RJ, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008; 248:994–1005.
54. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006; 13:58–65.
55. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004; 240:644–657. discussion 657-648.
56. Moris D, Vernadakis S, Papalampros A, et al. Mechanistic insights of rapid liver regeneration after associating liver partition and portal vein ligation for stage hepatectomy. World J Gastroenterol. 2016; 22:7613–7624.
57. Moris D, Dimitroulis D, Papalampros A, et al. ALPPS procedure for hepatocellular carcinoma in patients with chronic liver disease: revealing a terra incognita. Ann Surg. 2016.
58. Hagness M, Foss A, Egge TS. Dueland S: Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2014; 21:1323–1329.
59. Pikoulis E, Margonis GA, Andreatos N, et al. Prognostic role of BRAF mutations in colorectal cancer liver metastases. Anticancer Res. 2016; 36:4805–4811.
60. Shimomura M, Hinoi T, Kuroda S, et al. Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. Ann Surg Oncol. 2013; 20:S527–S536.
61. Dueland S, Guren TK, Hagness M, et al. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg. 2015; 261:956–960.
62. Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015; 26:702–708.
63. Tector AJ, Mangus RS, Chestovich P, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg. 2006; 244:439–450.
64. Nemes B, Gaman G, Polak WG, et al. Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation. Expert Rev Gastroenterol Hepatol. 2016; 10:841–859.
65. Hibi T, Itano O, Shinoda M, Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of “Transplant Oncology” has begun. Surg Today. 2016.